NCT07218575View on ClinicalTrials.gov

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2026

Primary Completion Date

April 30, 2030

Study Completion Date

April 30, 2030

Conditions
Cowden's DiseaseCowden's SyndromeLhermitte-Duclos DiseaseCerebellum Dysplastic GangliocytomaBannayan Zonana SyndromeMyhre Riley Smith SyndromeRiley Smith SyndromePTEN Hamartoma Tumor SyndromeBannayan Riley Ruvalcaba Syndrome
Interventions
DRUG

Everolimus blinded oral capsules

Oral capsules given once daily for the first 6 months

DRUG

Placebo

Oral capsules given once daily for the first 6 months

All Listed Sponsors
lead

Boston Children's Hospital

OTHER